302: Is the Fountain of Youth Finally Open for Business?
From CRISPR breakthroughs to AI-powered drug discovery, longevity science is moving from myth to marketplace. Host Andrew Wilkinson sits down with Alex Gunz, Portfolio Manager at Heptagon Capital, to explore how innovations in genomics, stem cells, and persona...
Show Notes
From CRISPR breakthroughs to AI-powered drug discovery, longevity science is moving from myth to marketplace. Host Andrew Wilkinson sits down with Alex Gunz, Portfolio Manager at Heptagon Capital, to explore how innovations in genomics, stem cells, and personalized medicine could redefine healthcare — and reshape the investment landscape. Discover why the race to extend lifespan may also unlock new long-term returns.
Episode Transcript
No transcript available for this episode.